Back

Circulating transthyretin tetramer as potential prognostic biomarker for outcome prediction in patients with heart failure

29 August 2026 (11:15 - 12:00)
Organised by: Logo
Congress Presentation Part of: Heart failure: diagnostics reimagined: electrocardiogram, artificial intelligence, and transthyretin amyloid cardiomyopathy Biomarkers ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Xinxin Zhang

First Affiliated Hospital of Dalian Medical University, Dalian (China)

6 More presentations in this session

Presentation thumbnail
Electrocardiographic correlates of disease burden in cardiac transthyretin amyloidosis
Doctor T. Krammer (Regensburg, DE)
Abstract Slides Video
Presentation thumbnail
Assessment of transthyretin tetramer stability in patients with ATTR‑CM using a novel probe‑based immunoassay
Associate Professor M. Nagao (JP)
Abstract Slides Video
Presentation thumbnail
Myocardial work in light-chain and transthyretin-related amyloidosis with preserved ejection fraction: a cardiac magnetic resonance study
Doctor S. Liang (Chengdu, CN)
Abstract Slides Video
Presentation thumbnail
Determinants of circulating transthyretin levels across the clinical spectrum of transthyretin amyloidosis
Professor T. Tsuruda (Miyazaki, JP)
Abstract Slides Video
Presentation thumbnail
Impact of serum transthyretin levels during disease-modifying therapy with tafamidis on cardiac parameters and long-term outcomes in patients with transthyretin amyloid cardiomyopathy
Mr Y. Kubota (JP)
Abstract Slides Video

Access the full session

Session thumbnail
Heart failure: diagnostics reimagined: electrocardiogram, artificial intelligence, and transthyretin amyloid cardiomyopathy

The Event

Event poster

ESC Congress 2026

29 August 2026 11:15 CET
You may be interested in
thumbnail
Congress Presentation
Serum transthyretin before and after starting tafamidis as outcome predictors in ATTR cardiomyopathy
9 May 2026
thumbnail
Congress Presentation
Do tafamidis and acoramidis improve survival and cardiovascular outcomes in transthyretin amyloid cardiomyopathy? a systematic review and meta-analysis
30 August 2026
thumbnail
Congress Presentation
CARDIO-TTRansform: efficacy and safety of eplontersen in patients with transthyretin amyloid cardiomyopathy
28 August 2026
thumbnail
Congress Session
Contemporary biomarkers for diagnosis, monitoring, and prognosis in heart failure
9 May 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources